{"id":"zd1839","safety":{"commonSideEffects":[{"rate":"75","effect":"Rash/dermatitis"},{"rate":"48","effect":"Diarrhea"},{"rate":"40","effect":"Nausea"},{"rate":"18","effect":"Vomiting"},{"rate":"25","effect":"Anorexia"},{"rate":"23","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ZD1839 selectively inhibits the intracellular tyrosine kinase domain of EGFR, preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors. It is an orally bioavailable small molecule designed to target EGFR-driven cancers.","oneSentence":"ZD1839 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling to inhibit cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:21.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07458919","phase":"EARLY_PHASE1","title":"Therapy for Advanced NSCLC With EGFR 19delins Mutation","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2026-03-30","conditions":"Lung Cancer","enrollment":94},{"nctId":"NCT07143045","phase":"","title":"A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","status":"RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2025-12-29","conditions":"EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases","enrollment":800},{"nctId":"NCT03040973","phase":"PHASE2","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-23","conditions":"Advanced Solid Tumors Which Are cMET-dependent","enrollment":29},{"nctId":"NCT06675695","phase":"","title":"Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":4864},{"nctId":"NCT02411448","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2015-05-06","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":545},{"nctId":"NCT03333343","phase":"PHASE1","title":"Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-01-29","conditions":"EGFR-mutant Non-small Cell Lung Cancer","enrollment":105},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03122717","phase":"PHASE1, PHASE2","title":"Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-09","conditions":"Non-Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT02856893","phase":"PHASE2","title":"Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-10-10","conditions":"NSCLC","enrollment":156},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT03292133","phase":"PHASE2","title":"A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-31","conditions":"Lung Cancer","enrollment":11},{"nctId":"NCT00328562","phase":"PHASE1","title":"ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2003-12","conditions":"Non-Small Cell Lung Carcinoma (NSCLC)","enrollment":13},{"nctId":"NCT03787992","phase":"PHASE3","title":"Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer","enrollment":358},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03944772","phase":"PHASE2","title":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":247},{"nctId":"NCT06071013","phase":"PHASE1, PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation","enrollment":20},{"nctId":"NCT06592989","phase":"","title":"A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-30","conditions":"Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib","enrollment":20},{"nctId":"NCT02588261","phase":"PHASE3","title":"A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":530},{"nctId":"NCT02347839","phase":"PHASE2","title":"NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2016-01-01","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT04248829","phase":"PHASE3","title":"Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2020-02-13","conditions":"Non-Small Cell Lung Cancer","enrollment":393},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT03866499","phase":"PHASE3","title":"A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beta Pharma Shanghai","startDate":"2021-04-30","conditions":"NSCLC","enrollment":369},{"nctId":"NCT01513174","phase":"PHASE1, PHASE2","title":"Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2011-08","conditions":"Non Small Cell Lung Cancer","enrollment":186},{"nctId":"NCT04143607","phase":"PHASE3","title":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2019-07-23","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":337},{"nctId":"NCT00198380","phase":"PHASE2","title":"Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2005-04","conditions":"Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature","enrollment":90},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":"Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma","enrollment":744},{"nctId":"NCT03647592","phase":"","title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-06-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT01185158","phase":"PHASE2","title":"A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2002-05","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT01485809","phase":"PHASE2","title":"Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy","status":"COMPLETED","sponsor":"Seoul Veterans Hospital","startDate":"2011-10","conditions":"Squamous Cell Carcinoma of Bronchus","enrollment":36},{"nctId":"NCT01774721","phase":"PHASE3","title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05-09","conditions":"Non-small Cell Lung Cancer With EGFR-Activating Mutations","enrollment":452},{"nctId":"NCT00483561","phase":"PHASE2","title":"Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-01","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT00352079","phase":"PHASE3","title":"BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-01-04","conditions":"Bladder Cancer","enrollment":41},{"nctId":"NCT04642547","phase":"NA","title":"Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2020-12-02","conditions":"Hepatocellular Carcinoma, Molecular Targeted Therapy","enrollment":30},{"nctId":"NCT01833572","phase":"PHASE2","title":"Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2013-05","conditions":"Non-small-cell Lung Cancer","enrollment":36},{"nctId":"NCT05934461","phase":"","title":"A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Laibin People's Hospital","startDate":"2014-12-01","conditions":"The Primary Study Metric is Progression-free Survival (PFS)","enrollment":48},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":312},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":462},{"nctId":"NCT01185171","phase":"PHASE2","title":"Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2003-01-27","conditions":"Head and Neck Cancer","enrollment":70},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT01994057","phase":"","title":"A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2012-09","conditions":"Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation","enrollment":1000},{"nctId":"NCT01570296","phase":"PHASE1","title":"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2011-10-03","conditions":"Non-Small Cell Lung Cancer, Solid Tumors","enrollment":38},{"nctId":"NCT03599518","phase":"PHASE1","title":"DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-09-21","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03849768","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2019-02-01","conditions":"Non Small Cell Lung Cancer","enrollment":429},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT01982955","phase":"PHASE1, PHASE2","title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-12-23","conditions":"Non-small Cell Lung Cancer","enrollment":88},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03758287","phase":"PHASE1, PHASE2","title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","status":"UNKNOWN","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer","enrollment":158},{"nctId":"NCT03170180","phase":"PHASE2","title":"Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-03-01","conditions":"Stomach Neoplasms","enrollment":66},{"nctId":"NCT02447419","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2014-12-03","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT00522145","phase":"PHASE2","title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2007-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":41},{"nctId":"NCT02088112","phase":"PHASE1","title":"MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2014-03-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":56},{"nctId":"NCT02932345","phase":"","title":"Gefitinib Long-term Survivor Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2016-10-31","conditions":"EGFR Mutation Positive Advanced Non-small-cell Lung Cancer","enrollment":59},{"nctId":"NCT01951469","phase":"PHASE3","title":"Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation","enrollment":160},{"nctId":"NCT03239015","phase":"PHASE2","title":"Efficacy and Safety of Precision Therapy in Refractory Tumor","status":"UNKNOWN","sponsor":"Baodong Qin","startDate":"2017-01-01","conditions":"Rare Tumor, Refractory Tumor","enrollment":300},{"nctId":"NCT00317772","phase":"PHASE1, PHASE2","title":"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-09-02","conditions":"Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer","enrollment":19},{"nctId":"NCT01288430","phase":"PHASE1","title":"A Study of DS-2248 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-03-29","conditions":"Solid Tumors, Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02736513","phase":"PHASE2","title":"Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2016-05","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03382795","phase":"PHASE2","title":"Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2018-01-03","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":63},{"nctId":"NCT02804776","phase":"PHASE2","title":"PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2015-01-27","conditions":"Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT04874844","phase":"PHASE2, PHASE3","title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","status":"UNKNOWN","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2021-07-30","conditions":"NSCLC","enrollment":420},{"nctId":"NCT01610336","phase":"PHASE2","title":"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04-05","conditions":"Non-small Cell Lung Cancer","enrollment":161},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT02025218","phase":"PHASE2","title":"Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-01","conditions":"Lung Cancer","enrollment":21},{"nctId":"NCT02747953","phase":"PHASE2","title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-07","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT02893332","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","status":"TERMINATED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2016-01-15","conditions":"Stage IV EGFR Mutated Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT04390984","phase":"PHASE1","title":"Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05-26","conditions":"NSCLC","enrollment":22},{"nctId":"NCT01556191","phase":"PHASE2","title":"Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-05-15","conditions":"Stage IV Lung Cancer","enrollment":379},{"nctId":"NCT02762877","phase":"","title":"Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Genomic Health®, Inc.","startDate":"2016-04","conditions":"Non Small Cell Lung Carcinoma","enrollment":140},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00052208","phase":"PHASE1, PHASE2","title":"Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-03","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":158},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT00553254","phase":"PHASE2","title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-05","conditions":"Carcinoma, Non Small Cell Lung","enrollment":55},{"nctId":"NCT01544179","phase":"PHASE3","title":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":265},{"nctId":"NCT03267654","phase":"PHASE2","title":"Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-10-12","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT03457337","phase":"PHASE2","title":"S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-03-28","conditions":"Advanced NSCLC With EGFR Mutation","enrollment":200},{"nctId":"NCT04425187","phase":"PHASE2","title":"Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-06-08","conditions":"PFS","enrollment":120},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT02374645","phase":"PHASE1","title":"A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2015-04","conditions":"Non-Small Cell Lung Cancer","enrollment":64},{"nctId":"NCT04358562","phase":"PHASE2","title":"Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-05-01","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation","enrollment":240},{"nctId":"NCT01466660","phase":"PHASE2","title":"LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-12-13","conditions":"Lung Neoplasms","enrollment":319},{"nctId":"NCT00025116","phase":"PHASE2","title":"ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2001-04-24","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT03119519","phase":"PHASE2","title":"Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2017-12-11","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":148},{"nctId":"NCT01405079","phase":"PHASE3","title":"Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2011-09-19","conditions":"Non-small Cell Lung Cancer","enrollment":222},{"nctId":"NCT01933347","phase":"PHASE2","title":"Third-line Treatment of Gefitinib in NSCLC Patients","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2014-04-07","conditions":"Non Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT04239833","phase":"PHASE3","title":"A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2020-01-31","conditions":"Non-Small Cell Lung Cancer","enrollment":240},{"nctId":"NCT02416739","phase":"PHASE2, PHASE3","title":"Anticancer Activity of Nicotinamide on Lung Cancer","status":"UNKNOWN","sponsor":"Il Yeong Park, Ph.D.","startDate":"2015-03","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT02745691","phase":"","title":"Psychometric Properties of the EORTC QLQ-LC29","status":"COMPLETED","sponsor":"University Hospital Regensburg","startDate":"2016-04-01","conditions":"Lung Cancer","enrollment":523},{"nctId":"NCT04193007","phase":"PHASE2","title":"The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2019-12-01","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":100},{"nctId":"NCT03529084","phase":"PHASE3","title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-24","conditions":"Carcinoma, Non-small Cell Lung","enrollment":""},{"nctId":"NCT02976116","phase":"PHASE2","title":"A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2016-12","conditions":"NSCLC","enrollment":50},{"nctId":"NCT04028778","phase":"PHASE3","title":"Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-04-10","conditions":"Lung Cancer, Nonsmall Cell","enrollment":310},{"nctId":"NCT00014183","phase":"PHASE2","title":"ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-01","conditions":"Kidney Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":460,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["gefitinib, Iressa ®","IRESSA","Iressa","Gefitinib","IRESSA®"],"phase":"phase_3","status":"active","brandName":"ZD1839","genericName":"ZD1839","companyName":"University of Chicago","companyId":"university-of-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZD1839 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling to inhibit cancer cell proliferation. Used for Non-small cell lung cancer (NSCLC), Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}